Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reissue Patent
2000-11-27
2008-03-18
Low, Christopher S. F. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S334000, C514S336000
Reissue Patent
active
RE040155
ABSTRACT:
In a preferred embodiment, drugs having chemotherapeutic properties which are useful against certain neoplastic disorders with wide safety margins as evidenced by their low toxicity, and molecular actions. Such drugs include as active ingredient(s) one or more N-substituted 2-(1H) pyridone(s) and/or N-substituted 3-(1H) pyridone(s). The compositions of this invention are novel as anti-neoplastic drugs, namelydelete-start id="DEL-S-00001" date="20080318" ?as an agent for treating leukemias, lymphomas, and leiomyomasdelete-end id="DEL-S-00001" ?insert-start id="INS-S-00001" date="20080318" ?as agent(s)for treating benign and malignant tumors, including lymphomas, leukemias, and leiomyomasinsert-end id="INS-S-00001" ?.
REFERENCES:
patent: 4042699 (1977-08-01), Gadekar
patent: 4052509 (1977-10-01), Gadekar
patent: 5962478 (1999-10-01), Margolin
patent: WO 96/27374 (1996-09-01), None
Ross, Russell, PhD. Medical Progress; The Pathogenesis of Athersclerosis—An Update; The New England Journal of Medicine vol. 314, No. 8, pp. 488, 493, 494; Department of Patholology, University of Washington School of Medicine, Seattle, Washington; Feb. 20, 1986.
Saven, Alan, M.D., et al.; Brief Communications, 2-Chlorodeoxyadenosine-induced Complete Remissions in Langerhans-Cell Histiocytosis, pp. 430-432; Reprint from Annals of Internal Medicine, vol. 121, No. 6, Sep. 15, 1994.
Schwartz, Stephen M., et al; Remodeling: How Vessels Narrow, Clinical Trials and Remoldeling; pp. 128-131; University of Washington, Seattle, WA; Massachusetts General Hospital, Boston, MA; and ZymoGenetics, Inc., Seattle WA. 1996.
Waltenberger, Johannes, M.D., Current Perspectives, Modulation of Growth Factor Action, Implications for the Treatment of Cardiovascular Diseases; Circulation, pp. 4083-4094; vol. 96, No. 11, Department of Internal Medicine II (Cardiology); Ulm University Medical Center, Ulm Germany; Dec. 2, 1997.
Copy of Brochure for Leustatin.RTM. (cladribine) Injection; Ortho Biotech, Raritan, New Jersey, Dec. 1996.
Lee et al., Pirfenidone: A Novel Pharmacological Agent That Inhibits Leimomyoma Cell Proliferation and Collegen Production, 1998, US, J. Clin. Endocrinal Metab 83: 219-223.
Crozier John H.
Gembeh Shirley V.
Low Christopher S. F.
LandOfFree
Methods for treatment of benign and malignant tumors,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treatment of benign and malignant tumors,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treatment of benign and malignant tumors,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3959979